A role model for translational medicine acceleration: Apricot BIO
Original article published by University Medicine Zurich – shortened version following.
Apricot BIO is considered the Google Maps of cell analysis – developing a process for quickly determining just the right medication for cancer patients.
According to founder Lucas Pekmans, «we founded Apricot BIO in September 2022. But our technology has a pretty long backstory». In a laboratory at UZH, they have been developing methods associated with imaging-based microscopy for a long time now, in combination with machine learning. Recognized as pioneers in this area, they were actually one of the first laboratories in Europe to use computational methods and artificial intelligence (AI) to source information from images of biological samples such as cells or tissue – and do so quickly.
«By way of comparison, you might describe this image-based form of systems biology as Google Maps for cells,» says CEO Michael Zering, «but instead of mapping districts and streets, we create a high-resolution map of both the inside of cells and the cellular environment». Thanks to automated microscopes and AI-supported image analysis, countless images of cells are taken and assessed – like satellite images, but at a microscopic scale. This allows us to identify how the cell structure changes when a medicine is introduced – «it is a bit like Google Maps, which shows where traffic is jammed or flowing freely». The more information available, the broader the context, which results in better decisions.
From researchers to entrepreneurs
Lucas Pelkmans and Michael Zering got to know each other through a network of local contacts in Zurich. The roles were quickly defined: Lucas brings his in-depth scientific know-how from the world of research to the table, while Michael strength is to see things from a corporate perspective. And both were clear about one thing: the field of cancer treatment has a lot of complex structures – and they saw an opportunity to put the latest scientific expertise into practice, in the hope of making a noticeable improvement in patient care. Apricot BIO was certainly not created on a whim. It was a carefully planned move.
From research to marketability
As the founders point out, they were very fortunate to be supported by the University of Zurich, the Translational Medicine Accelerator (TMA) and Unitectra – their expertise and resources were a decisive factor in helping us make the step from research to application.
The founding of a spin-off typically involves a transition from pure research to commercialization, something that presents a considerable challenge. This process involves developing a marketable application or product based on the results of research. It includes aspects such as product development, market analysis, business modeling, financing, legal framework conditions, and setting up a fully operational business. These hurdles need to be cleared in order to turn a scientific idea into a successful commercial enterprise.
The UZH Innovation Hub offers suitable support measures not only for bio & medtech innovation projects: Overview offerings.
